9 research outputs found

    Western blot of C3f and V65.

    No full text
    <p>(A) Reactivity of monoclonal and polyclonal antibodies anti-C3f (mAb-C3f and pAb-C3f respectively) to C3b (Complement C3b) and human vitronectin protein (V) on western blots. (B) Reactivity of polyclonal antibodies anti-V65 (pAb-V65) to C3b and vitronectin protein on western blots. (C) Reactivity of monoclonal antibody anti-C3f on Western blots of depleted and concentrated serum samples from OA and RA patients and synthetic C3f peptide. OA sample 1 and 2 were loaded at 21ng and 25ng per lane respectively. RA and C3f samples were loaded at 42ng and 7.5μg per lane respectively.</p

    C3f in human serum samples.

    No full text
    <p>(A) Measurements of C3f in μg/ml in serum samples from OA patients (n = 13), RA patients (n = 13) and NC (n = 13). All samples were analysed at 1 in 50 dilution. Concentration of C3f was significantly increased in the RA group in comparison to the OA and NC group (***p>0.0001) and no increase was observed for the OA group. Data were analysed using Kruskal-Wallis with post hoc Dunn’s analysis and plotted as means ± SEM. (B) Schematic representation of human C3 complement cleavage to generated C3a, C3b, C3f and iC3b fragments. (C) C3f sandwich ELISA performed on filtered serum samples from the 3 study groups. RA patient’s sample (n = 5) and 1 NC sample were filtered using 3kDa and 10kDa cut-off filter and assessed by C3f sandwich ELISA. Unfiltered serum were tested as control. Data plotted as means ± SEM.</p

    C3f and V65 ELISA development and validation.

    No full text
    <p>(A) A typical standard curve for C3f sandwich ELISA. Graph represent the log of C3f peptide concentration (from 0–1 μg/ml) against reading of optical density (OD) values fitted with nonlinear regression curve (Four Parameters Logistic Regression(4PL)). (B) Recovery of C3f peptide from spiked normal human serum diluted 1:50 to 1:400. C3f peptide was added at 1 μg/ml into assay buffer as positive control (C3f control) and to human serum diluted at 1:50, 1:100, 1:200 and 1:400 to test recovery. Diluted serum without spiked C3f was tested as negative control. Recovery of spiked C3f in serum was calculated in comparison to C3f control and showed 65%, 86%, 88% and 96% recovery at 1:50, 1:100, 1:200 and 1:400 dilutions respectively. Data plotted as means ± SEM. (C) A typical standard curve for V65 competitive ELISA. Graph represent the log of V65 peptide concentration (from 0–4 μg/ml) fitted with nonlinear regression curve (4PL). (D) Graph represent the concentration of V65 peptide against OD values. Spiking experiment was carried out with 2-fold serial dilution starting at 1μg/ml of V65 peptide using normal human serum (at 1:100 or 1:400). Data plotted as means ± SEM.</p

    Final conceptual model of the patient experience of stiffness in PMR and aspects that may be relevant to measurement of stiffness.

    No full text
    <p>This model reflects the major themes, derived from the data generated by participants with PMR, highlighting the importance of key symptoms and their impact on daily life: limiting function and a constant reminder. Pain and stiffness for many are inextricably linked, with one or other dominating their PMR experience or on occasion difficult to separate out. Outcome measures might address the intensity of symptoms and/or restriction of activities.</p
    corecore